NEW YORK (GenomeWeb News) - Affymetrix said today that it is working on a new technology that combines DNA sequencing and microarrays.

 

Speaking at the JPMorgan Healthcare Conference in San Francisco today, Stephen Fodor, Affy's chairman and CEO, said the company will deploy enzymatic sequencing reactions directly on arrays that have captured portions of the genome, using new chemistry that "allows us to use both polymerase and ligase labeling reactions."